DOCSLIB.ORG

The Association Between Seizures and Quinolone Antibiotics in Children: a Systematic Review of Adverse Events (Online Supplementary File)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Association Between Seizures and Quinolone Antibiotics in Children: a Systematic Review of Adverse Events (Online Supplementary File) The Association Between Seizures and Quinolone Antibiotics in Children: A Systematic Review of Adverse Events (Online Supplementary File) Search Strategy CENTRAL search strategy "quinolones":ti,ab,kw or "quinolone":ti,ab,kw or "ciprofloxacin":ti,ab,kw or "levofloxacin":ti,ab,kw (Word variations have been searched) AND "safety":ti,ab,kw or "adverse effect":ti,ab,kw or "adverse drug effect":ti,ab,kw or "adverse drug reaction":ti,ab,kw (Word variations have been searched) AND "pediatric":ti,ab,kw or "paediatric":ti,ab,kw or "infant":ti,ab,kw or "baby":ti,ab,kw or "neonate":ti,ab,kw (Word variations have been searched) EMBASE search strategy "(exp *CIPROFLOXACIN/ OR exp *OFLOXACIN/ OR exp *LEVOFLOXACIN/ OR exp *GATIFLOXACIN/ OR exp *MOXIFLOXACIN/) AND (exp *INFANT/ OR (exp *JUVENILE/ OR exp *CHILD/) OR exp *"PRESCHOOL CHILD"/ OR exp *ADOLESCENT/)" MEDLINE search strategy "(exp *CIPROFLOXACIN/ OR exp *OFLOXACIN/ OR exp *LEVOFLOXACIN/ OR exp *GATIFLOXACIN/ OR exp *MOXIFLOXACIN/) AND (exp *INFANT/ OR (exp *JUVENILE/ OR exp *CHILD/) OR exp *"PRESCHOOL CHILD"/ OR exp *ADOLESCENT/)" PUBMED search strategy ("adverse effects"[All Fields] OR "safety"[All Fields]) AND (((((((child[Title/Abstract] OR children[Title/Abstract]) OR infant[Title/Abstract]) OR pediatric[Title/Abstract]) OR paediatric[Title/Abstract]) OR pediatrics[Title/Abstract]) OR paediatrics[Title/Abstract]) AND ((("quinolones"[Title/Abstract] OR "fluroquinolones"[Title/Abstract]) OR "ciprofloxacin"[Title/Abstract]) OR "levofloxacin"[Title/Abstract])) List of References for Studies Included in Analysis 1. Abu-Arja RF, Gonzalez BE, Jacobs MR, et al. Disseminated Bacillus Calmette-Guerin (BCG) infection following allogeneic hematopoietic stem cell transplant in a patient with Bare Lymphocyte Syndrome type II. Transplant infectious disease : an official journal of the Transplantation Society. 2014;16(5):830-837. 2. Adler-Shohet FC, Low J, Carson M, Girma H, Singh J. Management of latent tuberculosis infection in child contacts of multidrug-resistant tuberculosis. The Pediatric infectious disease journal. 2014;33(6):664-666. 3. Ahmed AS, Khan NZ, Saha SK, et al. Ciprofloxacin treatment in preterm neonates in Bangladesh: lack of effects on growth and development. The Pediatric infectious disease journal. 2006;25(12):1137-1141. 1 4. Alam M, Haq S, Das K, et al. Efficacy of ciprofloxacin in enteric fever: comparison of treatment duration in sensitive and multidrug-resistant Salmonella. The American journal of tropical medicine and hygiene. 1995;53(3):306-311. 5. Angel CA, Green J, Swischuk L, Patel J. Severe ciprofloxacin-associated pseudomembranous colitis in an eight-year-old child. J Pediatr Surg. 2004;39(10):1590-1592. 6. Aquino VM, Herrera L, Sandler ES, Buchanan GR. Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer. Cancer. 2000;88(7):1710-1714. 7. Arguedas A, Sher L, Lopez E, et al. Open label, multicenter study of gatifloxacin treatment of recurrent otitis media and acute otitis media treatment failure. The Pediatric infectious disease journal. 2003;22(11):949-955. 8. Arguedas A, Dagan R, Pichichero M, et al. An open-label, double tympanocentesis study of levofloxacin therapy in children with, or at high risk for, recurrent or persistent acute otitis media. The Pediatric infectious disease journal. 2006;25(12):1102-1109. 9. Arora R, Gupta A, Joshi N, Kataria V, Lall P, Anand A. Multidrug resistant typhoid fever: study of an outbreak in Calcutta. Cough. 1992;39:37.38. 10. Atasoy H, Erdem G, Ceyhan M, Ecevit Z, Kanra G. Hypertension associated with ciprofloxacin use in an infant. The Annals of pharmacotherapy. 1995;29(10):1049. 11. Bannon M, Stutchfield P, Weindling A, Damjanovic V. Ciprofloxacin in neonatal Enterobacter cloacae septicaemia. Archives of disease in childhood. 1989;64(10 Spec No):1388-1391. 12. Belet N, Haciömeroğlu P, Küçüködük Ş. Ciprofloxacin Treatment in Newborns with Multi- Drug-Resistant Nosocomial PseudomonasInfections. Neonatology. 2004;85(4):263-268. 13. Bendig J, Kyle P, Giangrande P, Samson D, Azadian B. Two neutropenic patients with multiple resistant Pseudomonas aeruginosa septicaemia treated with ciprofloxacin. Journal of the Royal Society of Medicine. 1987;80(5):316. 14. Bethell DB, Hien TT, Phi LT, et al. Effects on growth of single short courses of fluoroquinolones. Archives of disease in childhood. 1996;74(1):44-46. 15. Bhutta ZA, Farooqui BJ, Sturm AW. Eradication of a multiple drug resistant Salmonella paratyphi A causing meningitis with ciprofloxacin. Journal of Infection. 1992;25(2):215-219. 16. Black A, Redmond AO, Steen HJ, Oborska IT. Tolerance and safety of ciprofloxacin in paediatric patients. The Journal of antimicrobial chemotherapy. 1990;26 Suppl F:25-29. 17. Brack E, Bodmer N, Simon A, et al. First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study. Pediatric blood & cancer. 2012;59(3):423-430. 18. Bradley JS, Arguedas A, Blumer JL, Saez-Llorens X, Melkote R, Noel GJ. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. The Pediatric infectious disease journal. 2007;26(10):868-878. 19. Brown N, Körner R, Zollman C, Martin R, Millar M. Ciprofloxacin treatment of bacterial endocarditis involving prosthetic material after cardiac surgery. Archives of disease in childhood. 1997;76(1):68-69. 20. Cannon PS, Mc Keag D, Radford R, Ataullah S, Leatherbarrow B. Our experience using primary oral antibiotics in the management of orbital cellulitis in a tertiary referral centre. Eye (London, England). 2009;23(3):612-615. 21. Chalumeau M, Tonnelier S, D’Athis P, et al. Pediatric Fluoroquinolone Safety Study Investigators: Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France. Pediatrics. 2003;111(6 pt 1). 22. Chauny JV, Lorrot M, Prot-Labarthe S, et al. Treatment of tuberculosis with levofloxacin or moxifloxacin: report of 6 pediatric cases. The Pediatric infectious disease journal. 2012;31(12):1309-1311. 2 23. Chien S, Wells TG, Blumer JL, et al. Levofloxacin pharmacokinetics in children. Journal of clinical pharmacology. 2005;45(2):153-160. 24. Choeyprasert W, Hongeng S, Anurathapan U, Pakakasama S. Bacteremia during neutropenic episodes in children undergoing hematopoietic stem cell transplantation with ciprofloxacin and penicillin prophylaxis. International journal of hematology. 2017;105(2):213-220. 25. Chotigeat U, Khorana M, Waranawat N. Successful treatment of late onset infection due to multi-drug resistant Acinetobacter Lwoffii in a low birth weight neonate using ciprofloxacin. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2001;84(6):910- 913. 26. Church DA, Kanga JF, Kuhn RJ, et al. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group. The Pediatric infectious disease journal. 1997;16(1):97-105; discussion 123-106. 27. Chysky V, Kapila K, Hullmann R, Arcieri G, Schacht P, Echols R. Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use. Emphasis on joint evaluation. Infection. 1991;19(4):289-296. 28. Connett GJ, Pike KC, Legg JP, et al. Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study. Therapeutic advances in respiratory disease. 2015;9(6):272-280. 29. Cuevas LE, Kazembe P, Mughogho GK, Tillotson GS, Hart CA. Eradication of nasopharyngeal carriage of Neisseria meningitidis in children and adults in rural Africa: a comparison of ciprofloxacin and rifampicin. The Journal of infectious diseases. 1995;171(3):728-731. 30. Dalle JH, Auvrignon A, Vassal G, Leverger G. Interaction between methotrexate and ciprofloxacin. Journal of pediatric hematology/oncology. 2002;24(4):321-322. 31. Davis H, McGoodwin E, Reed TG. Anaphylactoid reactions reported after treatment with ciprofloxacin. Annals of internal medicine. 1989;111(12):1041-1043. 32. Dey S. Nightmare due to ciprofloxacin in young patients. Indian pediatrics. 1995;32:918-918. 33. Doherty CP, Saha SK, Cutting WA. Typhoid fever, ciprofloxacin and growth in young children. Annals of tropical paediatrics. 2000;20(4):297-303. 34. Dolecek C, Tran TP, Nguyen NR, et al. A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam. PloS one. 2008;3(5):e2188. 35. Drossou-Agakidou V, Roilides E, Papakyriakidou-Koliouska P, et al. Use of ciprofloxacin in neonatal sepsis: lack of adverse effects up to one year. The Pediatric infectious disease journal. 2004;23(4):346-349. 36. Dutta P, Rasaily R, Saha M, et al. Ciprofloxacin for treatment of severe typhoid fever in children. Antimicrobial agents and chemotherapy. 1993;37(5):1197-1199. 37. Dutta S, Chowdhary G, Kumar P, Mukhopadhay K, Narang A. Ciprofloxacin administration to very low birth weight babies has no effect on linear growth in infancy. Journal of tropical pediatrics. 2006;52(2):103-106. 38. Esposito S, Tagliabue C, Bosis S, Principi N. Levofloxacin for the treatment of Mycoplasma pneumoniae-associated meningoencephalitis in childhood. International journal of antimicrobial agents. 2011;37(5):472-475. 39. Garazzino S, Scolfaro
Load more

Recommended publications
  • Defining Escherichia Coli As a Health-Promoting Microbe Against Intestinal Pseudomonas Aeruginosa
    bioRxiv preprint doi: https://doi.org/10.1101/612606; this version posted April 17, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Defining Escherichia coli as a health-promoting microbe against intestinal Pseudomonas aeruginosa Theodoulakis Christofi1, Stavria Panayidou1, Irini Dieronitou1, Christina Michael1 & Yiorgos Apidianakis1* 1Department of Biological Sciences, University of Cyprus, Nicosia, Cyprus *Corresponding author, email: [email protected] Abstract Gut microbiota acts as a barrier against intestinal pathogens, but species-specific protection of the host from infection remains relatively unexplored. Taking a Koch’s postulates approach in reverse to define health-promoting microbes we find that Escherichia coli naturally colonizes the gut of healthy mice, but it is depleted from the gut of antibiotic-treated mice, which become susceptible to intestinal colonization by Pseudomonas aeruginosa and concomitant mortality. Reintroduction of fecal bacteria and E. coli establishes a high titer of E. coli in the host intestine and increases defence against P. aeruginosa colonization and mortality. Moreover, diet is relevant in this process because high sugars or dietary fat favours E. coli fermentation to lactic acid and P. aeruginosa growth inhibition. To the contrary, low sugars allow P. aeruginosa to produce the oxidative agent pyocyanin that inhibits E. coli growth. Our results provide an explanation as to why P. aeruginosa doesn’t commonly infect the human gut, despite being a formidable microbe in lung and wound infections.
    [Show full text]
  • Lung Infections Aeruginosa Pseudomonas Hypersusceptibility
    TLRs 2 and 4 Are Not Involved in Hypersusceptibility to Acute Pseudomonas aeruginosa Lung Infections This information is current as Reuben Ramphal, Viviane Balloy, Michel Huerre, Mustapha of September 29, 2021. Si-Tahar and Michel Chignard J Immunol 2005; 175:3927-3934; ; doi: 10.4049/jimmunol.175.6.3927 http://www.jimmunol.org/content/175/6/3927 Downloaded from References This article cites 51 articles, 24 of which you can access for free at: http://www.jimmunol.org/content/175/6/3927.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 29, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology TLRs 2 and 4 Are Not Involved in Hypersusceptibility to Acute Pseudomonas aeruginosa Lung Infections1 Reuben Ramphal,* Viviane Balloy,† Michel Huerre,‡ Mustapha Si-Tahar,† and Michel Chignard2† TLRs are implicated in defense against microorganisms. Animal models have demonstrated that the susceptibility to a number of Gram-negative pathogens is linked to TLR4, and thus LPS of many Gram-negative bacteria have been implicated as virulence factors.
    [Show full text]
  • Research Journal of Pharmaceutical, Biological and Chemical Sciences
    ISSN: 0975-8585 Research Journal of Pharmaceutical, Biological and Chemical Sciences A contribution on Pseudomonas aeruginosa infection in African Catfish (Clarias gariepinus) Magdy, I.Hanna1 , Maha A. El-Hady2, Hanaa A. Ahmed 3, Saher A.Elmeadawy 4 and Amany M. Kenwy5 1Department of fish diseases and management, faculty of Vet. Med., Cairo University. 2epartment of fish diseases, Animal Health Research Institute, Dokki , Giza. 3Department of Biotechnology, Animal Health Research Institute, Dokki , Giza. 4Department of Biochemistry, Animal Health Research Institute, Dokki , Giza. 5Department of Hydrobiology, National Research Institute, Dokki , Giza. ABSTRACT In this study, samples from cultured Common carp (Cyprinus carpio), Nile tilapia (Oreochromis niloticus) and African catfish(Clarias gariepinus) fishes were collected from Kafr el-Sheikh, Menofya, Behira and Sharkia Governorates in Egypt for detection of Pseudomonas aeruginosa infection. Isolation and identification of Pseudomonas aeruginosa was done by traditional methods then confirmed using regular PCR technique. Pseudomonas aeruginosa gave 956 bp product size specific for 16S rDNA. The experimental inoculation of Clarias gariepinus with Pseudomonas aeruginosa was fully demonstrated. The most common clinical signs were external haemorrhage and ulcer with mortality rate 40%. Histopathological changes revealed degeneration and necrosis in all internal organs associated with hyperplesia in the wall of the blood vessels. Chronic inflammatory cell infiltration and melanomacrophage cells were detected in all fish tissues. The effect on some oxidative stress and immunological parameters of experimentally inoculated Clarias gariepinus with Pseudomonas aeruginosa were studied. Results revealed that there were significant increase in lipid peroxidation product (malondialdehyde) , hypoprotineamia, hypoalbuniaemia and hypoglobulinaemia. In-vitro sensitivity test of isolated Pseudomonas aeruginosa iitalosi to different chemotherapeutic agents was conducted.
    [Show full text]
  • 1 Title: Transmissible Strains of Pseudomonas Aeruginosa in Cystic
    ERJ Express. Published on February 9, 2012 as doi: 10.1183/09031936.00204411 Title: Transmissible strains of Pseudomonas aeruginosa in Cystic Fibrosis lung infections Authors: Joanne L. Fothergill1,2, Martin J. Walshaw3 and Craig Winstanley1,2 1Institute of Infection and Global Health, University of Liverpool, UK. 2NIHR Biomedical Research Centre in Microbial Diseases, Royal Liverpool University Hospital, Liverpool L69 3GA, UK. 3Liverpool Heart and Chest Hospital, Liverpool, UK. Corresponding Author: Prof. Craig Winstanley Department of Clinical Infection, Microbiology and Immunology Institute of Infection and Global Health University of Liverpool Apex Building West Derby St Liverpool L69 7BE Email: [email protected] 1 Copyright 2012 by the European Respiratory Society. Abstract: Pseudomonas aeruginosa chronic lung infections are the major cause of morbidity and mortality associated with cystic fibrosis (CF). For many years, the consensus was that CF patients acquire P. aeruginosa from the environment, and hence harbour their own individual clones. However, in the last 15 years the emergence of transmissible strains, in some cases associated with greater morbidity and increased antimicrobial resistance, has changed the way that many clinics treat their patients. Here we provide a summary of reported transmissible strains in the United Kingdom, other parts of Europe, Australia and North America. In particular, we discuss the prevalence, epidemiology, unusual genotypic and phenotypic features and virulence of the most intensively studied transmissible strain, the Liverpool Epidemic Strain. We also discuss the clinical impact of transmissible strains, in particular the diagnostic and infection control approaches adopted to counter their spread. Genomic analysis carried out so far has provided little evidence that transmissibility is due to shared genetic characteristics between different strains.
    [Show full text]
  • Pseudomonas Skin Infection Clinical Features, Epidemiology, and Management
    Am J Clin Dermatol 2011; 12 (3): 157-169 THERAPY IN PRACTICE 1175-0561/11/0003-0157/$49.95/0 ª 2011 Adis Data Information BV. All rights reserved. Pseudomonas Skin Infection Clinical Features, Epidemiology, and Management Douglas C. Wu,1 Wilson W. Chan,2 Andrei I. Metelitsa,1 Loretta Fiorillo1 and Andrew N. Lin1 1 Division of Dermatology, University of Alberta, Edmonton, Alberta, Canada 2 Department of Laboratory Medicine, Medical Microbiology, University of Alberta, Edmonton, Alberta, Canada Contents Abstract........................................................................................................... 158 1. Introduction . 158 1.1 Microbiology . 158 1.2 Pathogenesis . 158 1.3 Epidemiology: The Rise of Pseudomonas aeruginosa ............................................................. 158 2. Cutaneous Manifestations of P. aeruginosa Infection. 159 2.1 Primary P. aeruginosa Infections of the Skin . 159 2.1.1 Green Nail Syndrome. 159 2.1.2 Interdigital Infections . 159 2.1.3 Folliculitis . 159 2.1.4 Infections of the Ear . 160 2.2 P. aeruginosa Bacteremia . 160 2.2.1 Subcutaneous Nodules as a Sign of P. aeruginosa Bacteremia . 161 2.2.2 Ecthyma Gangrenosum . 161 2.2.3 Severe Skin and Soft Tissue Infection (SSTI): Gangrenous Cellulitis and Necrotizing Fasciitis. 161 2.2.4 Burn Wounds . 162 2.2.5 AIDS................................................................................................. 162 2.3 Other Cutaneous Manifestations . 162 3. Antimicrobial Therapy: General Principles . 163 3.1 The Development of Antibacterial Resistance . 163 3.2 Anti-Pseudomonal Agents . 163 3.3 Monotherapy versus Combination Therapy . 164 4. Antimicrobial Therapy: Specific Syndromes . 164 4.1 Primary P. aeruginosa Infections of the Skin . 164 4.1.1 Green Nail Syndrome. 164 4.1.2 Interdigital Infections . 165 4.1.3 Folliculitis .
    [Show full text]
  • Synergistic Antimicrobial Activity of Supplemented Medical-Grade Honey Against Pseudomonas Aeruginosa Biofilm Formation and Eradication
    antibiotics Article Synergistic Antimicrobial Activity of Supplemented Medical-Grade Honey against Pseudomonas aeruginosa Biofilm Formation and Eradication Carlos C. F. Pleeging 1,2,3, Tom Coenye 4 , Dimitris Mossialos 5 , Hilde de Rooster 1, Daniela Chrysostomou 6, Frank A. D. T. G. Wagener 2 and Niels A. J. Cremers 7,* 1 Small Animal Department, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Ghent, Belgium; [email protected] (C.C.F.P.); [email protected] (H.d.R.) 2 Department of Dentistry, Orthodontics and Craniofacial Biology, Radboud University Medical Center, Philips van Leydenlaan 25, 6525EX Nijmegen, The Netherlands; [email protected] 3 Dierenkliniek Parkstad, Bautscherweg 56, 6418EM Heerlen, The Netherlands 4 Laboratory of Pharmaceutical Microbiology, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium; [email protected] 5 Microbial Biotechnology-Molecular Bacteriology-Virology Laboratory, Department of Biochemistry and Biotechnology, University of Thessaly, Biopolis-Mezurlo, 41500 Larissa, Greece; [email protected] 6 Wound Clinic Health@45, Linksfield Road 45, Dowerglen, Johannesburg 1612, South Africa; [email protected] 7 Triticum Exploitatie BV, Sleperweg 44, 6222NK Maastricht, The Netherlands * Correspondence: [email protected]; Tel.: +31-43-325-1773 Received: 18 November 2020; Accepted: 2 December 2020; Published: 4 December 2020 Abstract: Biofilms hinder wound healing. Medical-grade honey (MGH) is a promising therapy because of its broad-spectrum antimicrobial activity and the lack of risk for resistance. This study investigated the inhibitory and eradicative activity against multidrug-resistant Pseudomonas aeruginosa biofilms by different established MGH-based wound care formulations. Six different natural wound care products (Medihoney, Revamil, Mebo, Melladerm, L-Mesitran Ointment, and L-Mesitran Soft) were tested in vitro.
    [Show full text]
  • ISSN: 2320-5407 Int. J. Adv. Res. 8(08), 691-694
    ISSN: 2320-5407 Int. J. Adv. Res. 8(08), 691-694 Journal Homepage: - www.journalijar.com Article DOI: 10.21474/IJAR01/11544 DOI URL: http://dx.doi.org/10.21474/IJAR01/11544 RESEARCH ARTICLE UNILATERAL AXILLARY LYMPHADENITIS CAUSED BY PSEUDOMONAS AERUGINOSA- A RARE CASE REPORT Dr. Sibabrata Bhattacharya1, Dr. Ankan Chakrabarti2 and Dr. Tapan Majumdar3 1. Associate Professor, Department of Microbiology, Agartala Government Medical College, Agartala, Tripura, India. 2. Post Graduate Trainee (3rd Year), Department of Microbiology, Agartala Government Medical College, Agartala, Tripura, India. 3. Professor & HOD, Department of Microbiology, Agartala Government Medical College, Agartala, Tripura, India. …………………………………………………………………………………………………….... Manuscript Info Abstract ……………………. ……………………………………………………………… Manuscript History Pseudomonas aeruginosa has been reported as the causative organism Received: 20 June 2020 of a wide spectrum of infections ranging from wound infections to fatal Final Accepted: 24 July 2020 Ventilator Associated Pneumonia (VAP), mainly in nosocomial and Published: August 2020 ICU setup. Patients usually have a known history of immunocompromised state, including burn patients and patients with Key words:- Pseudomonas Aeruginosa, Diabetes Mellitus. The recent advent of Carbapenem Resistant Lymphadenitis, Axillary Pseudomonas aeruginosa (CRPA) has presented with a unique Lymphadenopathy diagnostic and therapeutic challenge. Very few literatures exist regarding Pseudomonal infections manifesting as axillary lymphadenitis. Here, a case of unilateral axillary lymphadenopathy in an apparent immunocompetent host is reported from a tertiary care hospital in North Eastern India. Copy Right, IJAR, 2020,. All rights reserved. …………………………………………………………………………………………………….... Introduction:- Pseudomonas aeruginosa, a gram negative, aerobic bacillus, isubiquitous in nature and is usually implicated in a wide spectrum of serious infections in immunocompromised patients, burn patients, recent surgery, hospital admission, and bodywounds.[1].
    [Show full text]
  • Diverse Pseudomonas Aeruginosa Gene Products Stimulate Respiratory Epithelial Cells to Produce Interleukin-8
    Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8. E DiMango, … , R Bryan, A Prince J Clin Invest. 1995;96(5):2204-2210. https://doi.org/10.1172/JCI118275. Research Article Respiratory epithelial cells play a crucial role in the inflammatory response during Pseudomonas aeruginosa infection in the lungs of patients with cystic fibrosis. In this study, we determined whether the binding of specific Pseudomonas gene products (pilin, flagellin) to their receptors on respiratory epithelial cells would result in production of the neutrophil chemoattractant IL-8. Piliated wild-type organisms, purified pili, or antibody to the pilin receptor (asialoGM1) evoked significant production of IL-8 by immortalized airway epithelial cells, whereas nonpiliated organisms were less able to bind to respiratory epithelial cells and stimulated much less IL-8 secretion (P < 0.01). A piliated, nonflagellated strain was also associated with decreased binding and a diminished level of IL-8 production when compared to wild-type organisms. Isogenic, nonadherent rpoN mutants, lacking pilin and flagellin, did not bind or elicit an IL-8 response. In addition, the IL-8 response was four-fold higher in a cystic fibrosis cell line compared with its corrected cell line. The Pseudomonas autoinducer, an exoproduct secreted during chronic infection, was found to stimulate IL-8 in a dose-dependent manner. P. aeruginosa adhesins, which are necessary for initial infection, directly stimulate IL-8 production by respiratory epithelial cells and therefore play a major role in the pathogenesis of Pseudomonas infection in patients with cystic fibrosis. The inflammatory response is subsequently perpetuated by Pseudomonas autoinducer which is secreted during […] Find the latest version: https://jci.me/118275/pdf Diverse Pseudomonas aeruginosa Gene Products Stimulate Respiratory Epithelial Cells to Produce Interleukin-8 Emily DiMango, Heather J.
    [Show full text]
  • Phenotypic and Molecular Characterisation of Pseudomonas Aeruginosa Infections from Companion Animals and Potential Reservoirs of Antibacterial Resistance in Humans
    Phenotypic and molecular characterisation of Pseudomonas aeruginosa infections from companion animals and potential reservoirs of antibacterial resistance in humans. Thesis submitted in accordance with the requirements of the University of Liverpool for the degree of Master of Philosophy by Andrea Catherine Scott May 2018 Acknowledgements I would like to thank my primary supervisors Dr Joanne Fothergill and Dr Alan Radford. I also thank my secondary supervisors Dr Dorina Timofte, Dr Vanessa Schmidt, Dr Gina Pinschbeck and Dr Neil McEwan and the Institute of Infection and Global Health, University of Liverpool and Professor Craig Winstanley, along with the Small Animal Teaching Hospital (SATH), Leahurst, University of Liverpool and the Veterinary Diagnostic Laboratory (VDL), Leahurst. Matthew Moore (PhD student at University of Liverpool) performed Bioinformatics work for this project. The sequencing in this project was performed as part of the International Pseudomonas Consortium. The Masters thesis of this work was supported through a University of Liverpool/Wellcome Trust Research taster fellowship and internal funding. 2 Abbreviations AMR – Antimicrobial resistance BSAVA – British Small Animal Veterinary Association BVA – British Veterinary Association CDC - Centre for Disease Control and Prevention CF – Cystic fibrosis COPD – Chronic obstructive pulmonary disorder CRE – Carbepenam-resistant enterobacteriacea ECDPC - European Centre Disease Prevention and Control FDA – US Food and Drug Administration HAIs – Hospital acquired infections
    [Show full text]
  • IDSA/ATS Consensus Guidelines on The
    SUPPLEMENT ARTICLE Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults Lionel A. Mandell,1,a Richard G. Wunderink,2,a Antonio Anzueto,3,4 John G. Bartlett,7 G. Douglas Campbell,8 Nathan C. Dean,9,10 Scott F. Dowell,11 Thomas M. File, Jr.12,13 Daniel M. Musher,5,6 Michael S. Niederman,14,15 Antonio Torres,16 and Cynthia G. Whitney11 1McMaster University Medical School, Hamilton, Ontario, Canada; 2Northwestern University Feinberg School of Medicine, Chicago, Illinois; 3University of Texas Health Science Center and 4South Texas Veterans Health Care System, San Antonio, and 5Michael E. DeBakey Veterans Affairs Medical Center and 6Baylor College of Medicine, Houston, Texas; 7Johns Hopkins University School of Medicine, Baltimore, Maryland; 8Division of Pulmonary, Critical Care, and Sleep Medicine, University of Mississippi School of Medicine, Jackson; 9Division of Pulmonary and Critical Care Medicine, LDS Hospital, and 10University of Utah, Salt Lake City, Utah; 11Centers for Disease Control and Prevention, Atlanta, Georgia; 12Northeastern Ohio Universities College of Medicine, Rootstown, and 13Summa Health System, Akron, Ohio; 14State University of New York at Stony Brook, Stony Brook, and 15Department of Medicine, Winthrop University Hospital, Mineola, New York; and 16Cap de Servei de Pneumologia i Alle`rgia Respirato`ria, Institut Clı´nic del To`rax, Hospital Clı´nic de Barcelona, Facultat de Medicina, Universitat de Barcelona, Institut d’Investigacions Biome`diques August Pi i Sunyer, CIBER CB06/06/0028, Barcelona, Spain. EXECUTIVE SUMMARY priate starting point for consultation by specialists. Substantial overlap exists among the patients whom Improving the care of adult patients with community- these guidelines address and those discussed in the re- acquired pneumonia (CAP) has been the focus of many cently published guidelines for health care–associated different organizations, and several have developed pneumonia (HCAP).
    [Show full text]
  • Prevalence of Bacterial Infection Among Hospital Traumatic Patients
    2013 iMedPub Journals Vol. 2 No. 2:2 Our Site: http://www.imedpub.com/ JOURNAL OF BIOMEDICAL SCIENCES doi: 10.3823/1017 Abdulhamid M. Alkout1, Abdulaziz A. Zorgani2 3 Prevalence and Heyam Y. Abello 1 Medical Laboratory 3 Microbiology Department, Correspondence: of bacterial Department, Faculty of Medical Academic Postgraduate. Tripoli- Technology, University of Libya. [email protected] infection among Tripoli. Tripoli-Libya. 2 Medical Microbiology and Dr. Abdulaziz A. Zorgani, BSc, Immunology Department, DipBact, MSc, PhD Medical hospital traumatic Faculty of Medicine , University Microbiology and Immunology of Tripoli. Tripoli-Libya. Department, Faculty of Medicine , patients in relation University of Tripoli. Tripoli-Libya to ABO blood P.O. Box 12456 Tripoli-Libya. group Abstract Background: there are many studies demonstrated a correlation between blood group antigens and susceptibility to infectious diseases such as bacteria, parasites and viruses. Objectives: to assess the prevalence of bacterial infection among patients in the trauma hospital, and to assess the susceptibility of ABO blood groups to the isolated bacteria. Methods and Findings: 166 samples included, wound swabs, sputum and midstream urine were received for routine culture diagnostic procedures from the in-patients at Abosleem Traumatic Hospital and ABO group was obtained from Blood bank documented system for each patient. A correlation between isolated organisms and ABO system was determined. 51% patients were infected during their stay in the hospital by one of the following isolates: Pseudomonas (22%); Klebsiella (9%); Staphylococci (15%); and Streptococci (4%). The majority of in- patients belong to blood group O (45%), preceded by group A (37%); B (14%) and AB (4%). The distribution of different blood group within four main bacte- rial isolates was determined as following: 43% of blood group A patients were susceptible to pseudomonas; (27%) Klebsiella; (36%) Staphylococci; and (29%) Streptococci.
    [Show full text]
  • National Treatment Guidelines for Antimicrobial Use in Infectious Diseases
    National Treatment Guidelines for Antimicrobial Use in Infectious Diseases Version 1.0 (2016) NATIONAL CENTRE FOR DISEASE CONTROL Directorate General of Health Services Ministry of Health & Family Welfare Government of India CONTENTS Chapter 1 .................................................................................................................................................................................................................. 7 Introduction ........................................................................................................................................................................................................ 7 Chapter 2. ................................................................................................................................................................................................................. 9 Syndromic Approach For Empirical Therapy Of Common Infections.......................................................................................................... 9 A. Gastrointestinal & Intra-Abdominal Infections ......................................................................................................................................... 10 B. Central Nervous System Infections ........................................................................................................................................................... 13 C. Cardiovascular Infections .........................................................................................................................................................................
    [Show full text]